Evidence map›Paper›PMID 38028333›Full record

ArticleJournal of clinical and translational science2023

The Evolve to Next-Gen ACT Network: An evolving open-access, real-world data resource primed for real-world evidence research across the Clinical and Translational Science Award Consortium.

Elaine H Morrato, Lindsay A Lennox, James W Dearing, Anne T Coughlan, Elaina S Gano, Doug McFadden, Nallely Mora, Harold Alan Pincus, Gary S Firestein, Robert Toto and 1 more

Abstract read
In one paragraph

Article in Journal of clinical and translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Advancing regulatory science through real-world data and real-world evidence.Journal of clinical and translational science · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Elaine H MorratoParkinson School of Health Sciences and Public Health, Loyola University Chicago, Chicago, IL, USA.ORCID https://orcid.org/0000-0001-6105-7826
Lindsay A LennoxColorado Clinical and Translational Sciences Institute, CU Anschutz Medical Campus, Aurora, CO, USA.
James W DearingCollege of Communications, Arts and Sciences, Michigan State University, East Lansing, MI, USA.
Anne T CoughlanKellogg School of Management, Northwestern University, Evanston, IL, USA.
Elaina S GanoThe Chartis Group, Pittsburgh, PA, USA.
Doug McFaddenHarvard Catalyst, Harvard University, Boston, MA, USA.
Nallely MoraParkinson School of Health Sciences and Public Health, Loyola University Chicago, Chicago, IL, USA.
Harold Alan PincusIrving Institute for Clinical and Translational Research, Columbia University and New York State Psychiatric Institute, New York, NY, USA.
Gary S FiresteinAltman Clinical and Translational Research Institute at the University of California San Diego, San Diego, CA, USA.
Robert TotoCenter for Translational Medicine, UT Southwestern, Dallas, TX, USA.
Steven E ReisClinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA.

Funding

The Institute for Translational MedicineUL1TR002389 · NCATS · UNIVERSITY OF CHICAGO · PI Joshua J Jacobs, DAVID O MELTZER · 2017 to 2026
$71.6M
Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
NCATS NIH HHS UL1 TR001422NCATS NIH HHS UL1 TR002389
6 · The paper itself

Abstract

The ACT Network was funded by NIH to provide investigators from across the Clinical and Translational Science Award (CTSA) Consortium the ability to directly query national federated electronic health record (EHR) data for cohort discovery and feasibility assessment of multi-site studies. NIH refunded the program for expanded research application to become "Evolve to Next-Gen ACT" (ENACT). In parallel, the US Food and Drug Administration has been evaluating the use of real-world data (RWD), including EHR data, as sources of real-world evidence (RWE) for its regulatory decisions involving drug and biological products. Using insights from implementation science, six lessons learned from ACT for developing and sustaining RWD/RWE infrastructures and networks across the CTSA Consortium are presented in order to inform ENACT's development from the outset. Lessons include intentional institutional relationship management, end-user engagement, beta-testing, and customer-driven adaptation. The ENACT team is also conducting customer discovery interviews with CTSA hub and investigators using Innovation-Corps@NCATS (I-Corps™) methodology for biomedical entrepreneurs to uncover unmet RWD needs. Possible ENACT value proposition hypotheses are presented by stage of research. Developing evidence about methods for sustaining academically derived data infrastructures and support can advance the science of translation and support our nation's RWD/RWE research capacity.

Indexed as

Clinical and Translational Science Awardclinical informaticsdiffusion of innovationdisseminationelectronic health recordsimplementation sciencereal-world datareal-world evidencesustainabilityUS Food and Drug Administration

Identifiers

PMID38028333
PMCPMC10643916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.